RecruitingNCT05327023
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
PHASE1 · PHASE2 · 430 planned enrolment
- Countries listed
- 1
- Registry update
- September 18, 2026
immortal.lifeTrial registrations containing the exact intervention label Busulfan.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE1 · PHASE2 · 430 planned enrolment
PHASE1 · PHASE2 · 10 planned enrolment
PHASE1 · PHASE2 · 15 planned enrolment
PHASE1 · 0 planned enrolment